The authors wish to make the following corrections to this paper [1]:
AS01E was mistakenly referred to as in emulsion form, as below:
One of the most advanced subunit vaccines, M72:AS01, was recently shown to have 54% efficacy in HIV-negative individuals with latent TB when administered intramuscularly in emulsion form (denoted M72:AS01E) [40]. The adjuvant in this vaccine, AS01, consists of a mixture of the TLR4 ligand, MPLA, together with the saponin fraction QS21 in a liposomal or emulsion formulation [41].
This should be changed to the correct version, as follows:
One of the most advanced subunit vaccines, M72:AS01, was recently shown to have 54% efficacy in HIV-negative individuals with latent TB when administered intramuscularly (M72:AS01E) [40]. The adjuvant in this vaccine, AS01, consists of a mixture of the TLR4 ligand, MPLA, together with the saponin fraction QS21 in a liposomal formulation [41].
The authors would like to apologize for any inconvenience caused to the readers by these changes and state that the scientific conclusions are unaffected. The original publication has also been updated.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Reference
- 1.Stewart E., Triccas J.A., Petrovsky N. Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity. Microorganisms. 2019;7:255. doi: 10.3390/microorganisms7080255. [DOI] [PMC free article] [PubMed] [Google Scholar]